MedTrace Logo

The Study to YD312 Tablet in Patients With Diabetic Macular Edema

NCT03635814 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-01-09

No results posted yet for this study

Summary

This study objectives is to evaluate the efficacy of YD312 to improve visual acuity in patients with diabetic macular edema (DME) compared to placebo and determine optimal dose of phase 2b study.

Conditions

  • Diabetic Macular Edema(DME)

Interventions

DRUG

YD312 50mg

YD312 50mg \* 1 + placebo 6 tablets

DRUG

YD312 150mg

YD312 50mg \* 3 + placebo 6 tablets

DRUG

YD312 350mg

YD312 50mg \* 7 tablets

DRUG

Placebo

YD312 0mg \* 7 tabets

Sponsors & Collaborators

  • YD Global Life Science Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-19
Primary Completion
2018-07-27
Completion
2020-03-20
FDA Drug
Yes

Countries

  • United States
  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03635814 on ClinicalTrials.gov